MYLK4 promotes tumor progression through the activation of epidermal growth factor receptor signaling in osteosarcoma

Mengkai Yang†, Tao Zhang*,†, Yangfeng Zhang, Xiaojun Ma, Jing Han, Ke Zeng, Yafei Jiang, Zongyi Wang, Zhuoying Wang, Jing Xu, Yingqi Hua, Zhengdong Cai* and Wei Sun*

Abstract

Background: Osteosarcoma (OS) is the most common primary bone cancer in adolescents and lung metastasis is the leading cause of death in patients with OS. However, the molecular mechanisms that promote OS growth and metastasis remain unknown.

Methods: We investigated the expression of myosin light chain kinase family members between metastasis and non-metastasis patients in the TARGET database and ensured that only myosin light chain kinase family member 4 (MYLK4) had higher expression in metastatic osteosarcoma patients. Then we confirmed the results by immunohistochemistry (IHC) and Western blotting (WB) of OS tissues. The effect of MYLK4 on the metastasis and proliferation of OS cells was investigated by wound healing, Transwell and colony-formation assays. Mass spectrum analysis was used to ensure the new binding protein of MYLK4. Tissue microarrays analysis was used to show the correlation between MYLK4 and pEGFR (Y1068). A series of in vivo experiments were conducted to reveal the mechanisms by which MYLK4 modulated the metastasis and proliferation of OS.

Results: Myosin Light Chain Kinase Family Member 4 (MYLK4) was significantly upregulated in metastatic human OS tissues. Growth and metastasis of OS could be accelerated by MYLK4 overexpression, whereas silencing MYLK4 expression resulted in decreased cell growth and metastasis. Mechanistically, mass spectrum analysis showed that MYLK4 interacted with the epidermal growth factor receptor (EGFR) in osteosarcoma cells and promoted growth and metastasis via the EGFR signaling pathway. Tissue microarrays analysis also showed that MYLK4 expression had a positive correlation with the expression of pEGFR (Y1068). Moreover, the EGFR inhibitor gefitinib could partially reverse the effect of cell proliferation and metastasis caused by MYLK4 overexpression. Importantly, the combination of MYLK4 and EGFR inhibitors had synergistic effects on growth and metastasis of OS in vitro and in vivo.

Conclusion: Our results indicate that MYLK4 promotes OS growth and metastasis by activating the EGFR signaling pathway and can be a novel therapeutic target for the treatment of OS patients.

Keywords: MYLK4, Osteosarcoma, Epidermal growth factor receptor, Growth, Metastasis

* Correspondence: zhangtaoabc@2008.sina.com; czd856@vip.163.com; viv-sun@163.com
†Mengkai Yang and Tao Zhang contributed equally to this work.
Department of Orthopedics, Shanghai Bone Tumor Institution, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, P. R. China

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Osteosarcoma (OS) is the most common bone tumor and is often found in adolescents [1]. Primary OS has a five-year survival rate of 69%, but when the tumor metastasizes, the survival rate is only 15–30% [2]. It has been reported that 20% of patients with OS have a distant metastasis when they are first diagnosed [3]. Among the numerous causes of death in patients with OS, lung metastasis causes the highest mortality. Thus, it is necessary to explore the underlying molecular mechanisms in distant metastasis of OS.

Myosin light chain kinase (MYLK) was discovered approximately 40 years ago as a skeletal and smooth muscle enzyme [4]. Since then, knowledge regarding MYLK has gradually increased. The MYLK family is made up of four different kinases (MYLK, MYLK2, MYLK3, and MYLK4) that are encoded by different genes [5]. Numerous cell activities, such as cell migration, invasion, and proliferation, are influenced by MYLK [6]. Dynamic changes in the cytoskeleton are necessary for invasion and metastasis potential of cancer cells. Cytoskeletal myosin II phosphorylated by MYLK increases the metastatic potential of tumor cells, and MYLK-dependent cytoskeleton rearrangement adjusts the angiogenesis of the vascular endothelial barrier, which is an inevitable step in cancer metastasis [7]. Bao et al. found through bioinformatics analysis that MYLK2 was associated with poor prognosis in triple-negative breast cancer [8]. For those with hepatocellular carcinoma, Wang et al. indicated that MYLK2 was upregulated in tumor tissues and was linked with a lower survival rate [9]. However, studies on MYLK3 and MYLK4 are limited. MYLK3 has an important role in preventing cardiomyocyte atrophy [10]. Moreover, in patients with heart failure, MYLK4 has a vital role in the altered cytoskeletal network of cardiomyocytes [11]. Lee et al. found that MYLK4 was a monoauxilially expressed gene through high-density single nucleotide polymorphism chips that have an important role in the development of colorectal cancer cells [12]. Although MYLK family members were found to be associated with the development of tumors in previous studies, how they are involved in the growth and metastasis of OS remains unclear.

Cell surface receptors that can be stimulated by various growth factors can promote the proliferation and invasion of multiple cancers. As transmembrane protein receptors, receptor tyrosine kinases such as the epidermal growth factor receptor (EGFR) have an important effect on cell physiology [13]. EGFR overexpression is generally found in many types of human cancer and is currently used in multiple cancer treatment targets in clinical practice [14]. A poor prognosis in those with certain cancers such as cervical, bladder, head and neck, and ovarian cancers, has been found to have an important correlation with EGFR overexpression [15]. In patients with OS, high EGFR expression is also associated with high proliferation activity and metastasis potential, as well as poor prognosis [16]. In addition, dysfunction of signaling in several downstream EGFR pathways such as PI3K/AKT and JAK/STAT3 has also been implicated in OS development and metastasis [17, 18]. Recently, numerous EGFR antibodies and inhibitors have shown substantial application potential in tumor therapy [19]. In one clinical trial, EGFR inhibitors were shown to have good therapeutic effect for those with OS [20]. Whether the EGFR signaling pathway could be affected by MYLK4 in those with OS needs to be further investigated.

In the present study, we found that MYLK4 interacted with EGFR. This interaction promoted OS progression through the EGFR signaling pathway in vivo and in vitro. MYLK4 overexpression led to EGFR phosphorylation, whereas MYLK4 knockdown reduced EGFR phosphorylation. More importantly, we demonstrated that the combination of MYLK4 and EGFR inhibitors exhibits a promising synergistic effect for OS treatment. In general, this study demonstrated that MYLK4 promotes OS proliferation and metastasis via the activation of the EGFR signaling pathway.

Materials and methods
Database analysis
We downloaded the mRNA expression data of patients with OS from the genomic data commons data portal (https://portal.gdc.cancer.gov/). Complete clinical information of the above patients were downloaded from the TARGET database (https://ocg.cancer.gov/programs/target). There were 85 patients included in this database. The clinical information in the TARGET datasets were shown in Supplementary table 1. The univariate cox regression analysis was used to assess the correlation between gene expressions and prognosis of OS patients. The mRNA expression data of OS samples in GSE12865 which contained two normal samples were downloaded from the NCBI gene expression omnibus (https://www.ncbi.nlm.nih.gov/geo/, GSE12865).

Survival analyses
We compared the overall survival of OS patients between high-MYLK4 group and low-MYLK4 group. We performed the log-rank test to verify if the differences in survival time were significant. Kaplan-Meier curves were used to visualize the survival of different groups and the differences among them.

Cells and cell culture
The Cell lines 143B (human OS cells), U2OS (human OS cells), SAOS2 (human OS cells), HOS (human OS cells), MG63 (human OS cells), SJSA-1 (human OS cells) and HEK-293 T cell lines were obtained from ATCC (Manassas, VA, USA). MG63.2 cell was derived from the
metastasis of parental MG63, as previously reported [21]. All cell lines were maintained in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin in a humidified incubator at 37°C and 5% CO2. These cell lines were mycoplasma-free and routinely authenticated by quality examinations of morphology and growth profile.

**Cell transfection**
The plasmids coding for human MYLK4, EGFR and relevant empty plasmid were obtained from Youbio Biological Technology Co., Ltd. (Changsha, China). The MYLK4 lentiviral shRNA plasmid was supplied by Genomeditech (Shanghai, China). The sequences targeting MYLK4 were as follows: shMYLK4–1, CCGGATCGATGAGAGCTACAATTTGCTCGAGCAAATTGTAGCTC1CATCGATT1TTT1G, shMYLK4–2, CGGCATCCTATATGCTACTTAGCTCGAGCTAAGTAGCATATAGGCATT1TT1TG.

The lentivirus was acquired in HEK293T cells. We co-transfected indicated plasmids and helper virus packaging plasmids pMD2.G and psPAX2 by using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) in HEK293T cells. Following infection for 48 h, supernatants containing lentivirus were harvested.

**Immunofluorescence (IF) staining**
All the cells were fixed in 4% paraformaldehyde, permeabilized with 0.5% Triton X-100 and incubated with Alexa Fluor 594 phalloidin for 90 min (Abcam, MA, USA). Then, the cells were incubated with DAPI for 10 min (Beyotime, Shanghai, China). Immunofluorescence images were obtained by using fluorescent microscope (Leica, Germany).

**Cell proliferation and colony-formation assays**
Cell proliferation was estimated by the Cell Counting Kit-8 (CCK8) (Dojindo, Tokyo, Japan) based on the manufacturer's instructions. For colony-formation assays, cells were plated in six-well plates at a density of 500 cells per well and incubated at 37°C for two weeks until the cells grew to visible colonies. Then, the medium was discarded and the remaining cells were washed with PBS for three times. Colonies were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet for 15 min.

**Transwell invasion assay**
Cell invasion capabilities were detected by using Transwell chambers precoated with the Matrigel matrix as previously described [22]. Cells were seeded into the upper compartments at a density of 5 × 10^4 cells/well in 100 μl serum-free media and the lower chamber were added 600 μl DMEM with 10% fetal bovine serum as a chemo-attractant. After which the plates were incubated for 12 h at 37°C. The non-invaded cells were mildly removed from the upper chamber using a cotton swab and the invaded cells on the bottom surface were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. Images were acquired by an inverted microscope (Olympus), and the invaded cells were counted manually.

**Wound-healing migration assay**
Wound-healing migration assay was performed as previously described [22]. Cells were seeded in six-well plates and grew until they reached full confluence. Use a sterile 100 μl pipette tip to create a “wound”. Observe the breadth of “wound” at different time points with a fluorescence microscope (Olympus). The distances were measured by ImageJ software (National Institutes of Health, MD).

**Co-immunoprecipitation assay**
Co-immunoprecipitation (Co-IP) assay was performed using 143B and HEK-293 T cells. The protein lysate was extracted by NP40 (Beyotime, P0013F) for 30 min on ice, and centrifuged at 12,000×g for 20 min. Every 1 μg of the primary antibody or IgG were mixed with 500 μg total proteins and then were shaken for 1 h at 4°C. At last, the Protein G beads (Santa Cruz Biotechnology, USA) were added to the mixture and shaken at 4°C overnight. The beads were then washed 3 times using immunoprecipitation buffer. Loading buffer (2x) was mixed with the beads and boiled for 15 min. Then the samples were used for western blot analysis.

**Western blotting**
Cells and tumor tissues were lysed with RIPA buffer (Beyotime, Shanghai, China) which was mixed in advance with a protease and a phosphatase inhibitor cocktail (Sigma-Aldrich, USA) for 30 min on ice. After centrifugation at 12,000×g for 20 min at 4°C, the supernatants were collected and quantified using BCA assay (Beyotime, Shanghai, China). These membranes were incubated with 5% non-fat milk dissolved by TBST and then incubated with primary antibody or IgG were mixed with 50 μg of each sample was resolved on SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes through Bio-Rad (Hercules, CA, USA). These membranes were incubated with 5% non-fat milk dissolved by TBST (TBS and 0.1% Tween20) for 1 h at room temperature and incubated overnight at 4°C with primary antibodies. The next day, membranes were washed with TBST for three times every ten minutes and then incubated with secondary antibody (Sigma-Aldrich). After washing three times, signals were detected through ECL detection reagents. Primary antibodies: P-EGFR (Tyr1068) (#3777, Cell Signaling), EGFR (#4267, Cell Signaling), P-AKT (#4060, Cell Signaling), AKT (#4685, Cell Signaling), P-ERK (#4370, Cell Signaling), ERK (#4695, Cell Signaling), MYLK4 (24309–1-AP, Proteintech).
Mass spectrometry analysis
The analysis was performed in an HPLC system (Easy nLC1000, Thermo Fisher Scientific, USA) and mass spectrometer (Orbitrap Elite, Thermo Fisher Scientific, USA). The IP beads were collected from a 10 cm dish of Flag-MYLK4 overexpression 143B cells. The samples were subjected to western blot and then stained by silver staining.

Immunohistochemistry (IHC)
IHC assays were conducted as reported previously [22]. OS tissue array was stained with anti-MYLK4 antibody and anti-P-EGFR (Y1068) antibody. Images were obtained with Leica microscope (Leica, DM4000b). The immunohistochemical scores were calculated by formula as followed. H-SCORE = Σ(PI×I) = (percentage of cells of weak intensity *1) + (percentage of cells of moderate intensity *2) + (percentage of cells of strong intensity *3).

His-tag pull-down assay
GST-MYLK4 and His-EGFR (668–1210) were expressed in bacteria and purified in accordance with the manufacturer’s instructions. Then, 10 μg of His-EGFR was mixed with 10 μg of GST-MYLK4 or GST and incubated with Ni-NTA agarose, for the His-tag pull-down assay. The pellets were washed three times and boiled in SDS buffer for 10 min. At last, we examined the bound proteins by western blot with anti-GST and anti-His tag.

In vitro kinase assay
For in vitro kinase assays, GST-MYLK4 purified protein was incubated with His-EGFR (668–1210) purified protein at 30 °C in a total volume of 30 ml of kinase assay buffer for 1 h. The reaction mixtures were stopped by SDS buffer and analyzed by Western blots using pIMAGO for phosphoprotein detection on western blot kit (TYMORA, 800–10).

In vivo animal experiments
The animal experiments were approved by the Animal Research Committee of the Shanghai General Hospital (Ethical code: 2019AW004) and were performed in accordance with established guidelines. For the growth and metastasis assays in vivo, four-week-old male nude mice were orthotopically inoculated into the right tibia with a micro syringe, too. 143B cells were harvested and washed three times with cold PBS. Then, total of 1 × 10⁶ cells suspended in 20 μL of PBS were injected into the medullary cavity of the tibia. When the tumors in the tibia were macroscopically visible, the mice were randomly divided into four groups: control group, ML-7, Gefitinib single treated group and ML-7 plus Gefitinib treated group and respectively received i.p. injection of gefitinib (50 mg/kg per 2 days), ML-7 (1 mg/kg per 2 days), the combination of gefitinib (50 mg/kg per 2 days) and ML-7 (1 mg/kg per 2 days) as compared with mice injected with DMSO (control group). One month later, all mice were killed, the tumors and individual lung tissues were excised and fixed with 4% paraformaldehyde. Metastatic lung tissues were analyzed by H&E staining.

Hematoxylin and eosin staining
Lung tissues were fixed overnight, embedded in paraffin and then cut into serial sections (4-μm thick). The sections were subjected to hematoxylin and eosin (H&E) staining. Representative images were acquired using a microscope (Leica).

Statistical analysis
All data are presented as mean ± standard derivation (S.D.). The Student t test was used for the comparison of measurable variants of two groups (P < 0.05 was considered significant) unless otherwise indicated. All experiments were performed at least three times except for the experiments using the animal models. The variance per assay was similar between the groups statistically compared. No data points in our study were excluded.

Results
MYLK4 is upregulated in metastatic OS tissues
In order to illuminate the function and clinical importance of myosin light chain kinase family members (MYLK, MYLK2, MYLK3 and MYLK4) in OS, we first analyzed MYLK, MYLK2, MYLK3, and MYLK4 expression using the Therapeutically Applicable Research to Generate Effective Treatments database to understand the function and clinical importance of the MYLK family. We found that only MYLK4 had a higher expression in patients with OS during metastasis (P = 0.0415) (Fig. 1a; Supplementary Fig. 1A-C). Furthermore, we used an immunohistochemistry assay to determine whether MYLK4 expression is related to OS metastasis. We found that MYLK4 expression was higher in metastatic OS tissues than that in non-metastatic tissues (Fig. 1b and c). The clinical characteristics of the osteosarcoma patients in immunohistochemistry assay were shown in Supplementary table 2. Additionally, we examined MYLK4 protein levels in these samples through Western blot analysis and found that metastatic OS
tissues had higher MYLK4 protein levels than that in the non-metastatic groups (Fig. 1d). Furthermore, using data from the patient cohort obtained in the database, the Kaplan-Meier (KM) analysis showed that patients with high expression of MYLK4 had lower overall survival rates and event-free survival rates than patients with low expression of MYLK4 (Fig. 1e and f). The survival time of the osteosarcoma patients in TARGET database was shown in Supplementary table 3. We also found that only MYLK4 had higher expression in OS tissues than that in normal human osteoblasts in GSE12865 (Supplementary Fig. 1D-G), and we verified that MYLK4 was generally expressed in OS cell lines (Supplementary Fig. 1H). We also found that U2OS, Saos2 and MG63 had lower expressions than SJSA-1, HOS, MG63.2 and 143B. These results demonstrate that MYLK4 shows high expressions in metastasis OS samples and can be a risk factor in OS patients.

MYLK4 promotes OS metastasis

Cell migration and invasion is a critical step in tumor metastasis. Lung metastasis is the most common transference process of OS patients, which is the major cause of death in OS patients. The MYLK family members have been proved to have effect on metastasis in many tumors, but the role of MYLK4 in OS is poorly understood. Therefore, we explored the function of MYLK4 on OS cell migration and invasion. In order to investigate the causal role of MYLK4 played in OS progression, we constructed MYLK4 down-regulation HOS and 143B stable cell lines, also MYLK4 overexpression U2OS and
Saos2 stable cell lines (Fig. 2a, d). Results of the “wound healing” migration assay indicated that MYLK4 overexpression or knockdown significantly promoted or inhibited cell migration in corresponding OS cells, respectively (Fig. 2b, e). The result of Transwell invasion assay also obtained similar result (Fig. 2c, f). Moreover, we investigated whether the function of MYLK4 in OS cells promoted the epithelial to mesenchymal transition (EMT) process. E-cadherin is the epithelial marker while N-cadherin, Twist and Snail are the mesenchymal marker in EMT [23]. As shown in Fig. 2g, MYLK4 knockdown suppressed N-cadherin and Twist and Snail expression and increased E-cadherin expression. By contrast, MYLK4 overexpression increased N-cadherin and Twist and Snail expression and suppressed E-cadherin suppression. Furthermore, we found that TGF-β can be induce MYLK4 expression in OS cells (Supplementary Fig. 2A). Meanwhile, MYLK4 knockdown slowed down the induction EMT effect of TGF-β in OS cells (Supplementary Fig. 2B). In addition, we detected the effect of MYLK4 on cytoskeletal organization of the OS cell. The F-actin stress fibers were observed by Alexa Fluor 594 phalloidin. The result showed that the number of F-actin stress fibers in MYLK knockdown cells were reduced in Supplementary Fig. 3. Next, we further verified the role of MYLK4 in OS metastasis in vivo. Because the two shRNA have almost the same efficiency (Fig. 2d), we choose shRNA-1 for animal experiment. The numbers of lung metastatic nodules in MYLK4-knockdown orthotopic OS-implanted mice were fewer than those in the control group (Fig. 2h). Taken together, these findings suggest that MYLK4 could promote OS metastasis by regulating cell migration, invasion, and EMT process.

**MYLK4 increases OS cell proliferation**

According to the result of animal experiment, we also found MYLK4-knockdown orthotopic osteosarcoma implanted mice not only had the reduced lung metastasis, but also had the smaller tumor weight (Fig. 3a). We also detected the efficiency of shRNA in vivo, we found the expression of MYLK4 is significantly reduced in shMYLK4 group (Fig. 3b). Immunohistochemical staining results showed that the percentage of Ki67-positive cells was lower in orthotopic OS implanted-mice due to MYLK4 knockdown in 143B cells (Fig. 3c). Therefore we wonder whether MYLK4 also plays an important role in cell growth and proliferation of OS. Our results demonstrated that MYLK4 overexpression in U2OS and Saos2 stable cell lines accelerated proliferation and colony-formation ability compared to that in the control (Fig. 3d and e). Inversely, MYLK4 knockdown in 143B and HOS stable cell lines inhibited proliferation and colony-formation ability (Fig. 3f and g). Therefore, this results indicate that MYLK4 could also promote OS cell proliferation.

**MYLK4 interacted with EGFR**

To further study the underlying mechanism by which MYLK4 promoted OS growth and metastasis, we performed mass spectrometry followed by silver staining in 143B-MYLK4-FLAG cell line and confirmed the EGFR as one of the new potential proteins interacting with MYLK4 based on the mass spectrometry results (Fig. 4a and b) (Supplementary table 4). Moreover, the interaction between MYLK4 and the EGFR was verified based on the results of immunoprecipitation experiments using 143B stably expressing MYLK4-FLAG (Fig. 4c). Furthermore, the presence of the EGFR was detected by the immunoprecipitation of endogenous MYLK4, and the endogenous EGFR was detected in the 143B cell line based on the results of the reciprocal Co-IP assays (Fig. 4d). Reciprocal Co-IP assays also indicated that the exogenous EGFR and MYLK4 interact with each other in 293 T (Fig. 4e). Taken together, these results strongly support that the EGFR is a bona fide binding protein of MYLK4.

**MYLK4 enhances the EGFR signaling pathway in OS**

Since MYLK4 has an interaction with EGFR, we further to find that whether MYLK4 could promote the phosphorylation of EGFR and enhance the EGFR signaling. Our results demonstrated that MYLK4 overexpression in U2OSs and Saos2 cell lines promoted the EGFR signal pathway, as evidenced by increased expression of p-EGFR, p-AKT, and p-ERK. Conversely, MYLK4 knockdown restrained EGFR signaling in OS cells (Fig. 5a and b). Next, we detected the changes of EGFR phosphorylation following epidermal growth factor (EGF) stimulation for 15 min between MYLK4-knockdown cells and the control cells and found MYLK4-knockdown cells exhibited EGFR phosphorylation decrease, along with p-AKT and p-ERK downregulation (Fig. 5c). Then we further the changes of EGFR phosphorylation following EGF stimulation for a 120-min time course and also found that knockdown of MYLK4 restrained the activation of the EGFR signaling pathway in HOS and 143B cells treated with EGF (Fig. 5d). In order to investigate the correlation between MYLK4 and EGFR (Y1068) in OS, their expression levels were measured in 47 human OS tissues by Immunohistochemistry (IHC). IHC results showed a positive correlation between the expression of MYLK4 and p-EGFR (Y1068) and the Spearman correlation coefficient was 0.5511 and p < 0.01 (Fig. 5e and f). In addition, we treated the 143B-MYLK4-FLAG cell line with or without 25 mM Gefitinib for 24 h. Then the phosphorylated MYLK4 was detected by anti-Phospho-Tyrosine antibody. The result in Supplementary Fig. 4A showed that the expression of p-Tyr of MYLK4 didn’t change after the stimulation of Gefitinib. It meant that EGFR couldn’t phosphorylate MYLK4. Furthermore, we
Fig. 2 MYLK4 promotes osteosarcoma cell metastasis in vivo and in vitro. a The MYLK4 overexpression effects were confirmed by western blotting. b The effect of MYLK4 overexpression on OS cell migration was assessed by a wound healing assay. Representative images of migration were shown in the left panel. The degrees to which the wounds healed in the indicated groups were shown in the histogram. The bars indicate the mean ± s.d. Statistically significant differences (t-test), **P < 0.01, Scale bars = 250 μm. c The effect of MYLK4 overexpression on OS cell invasion was assessed by a transwell assay (left panel). The relative proportions of invading cells were shown in the histogram. The bars indicate the mean ± s.d. Statistically significant differences (t-test), **P < 0.01, Scale bars = 200 μm. d The MYLK4 knockdown effects were confirmed by western blotting. e The effect of MYLK4 knockdown on OS cell migration was assessed by a wound healing assay. Representative images of migration were shown in the left panel. The degrees to which the wounds healed in the indicated groups were shown in the histogram. The bars indicate the mean ± s.d. Statistically significant differences (t-test), **P < 0.01, Scale bars = 250 μm. f The effect of MYLK4 knockdown on OS cell invasion was assessed by a transwell assay (left panel). The relative proportions of invading cells were shown in the histogram. The bars indicate the mean ± s.d. Statistically significant differences (t-test), **P < 0.01, Scale bars = 200 μm. g The expression of EMT markers was detected by western blotting in MYLK4 over-expression and MYLK4-knockdown OS cells. h The number of lung metastasis nodules formed by MYLK4-knockdown 143B cells and control cells in orthotopic osteosarcoma implanted mice was shown in the right panel. Statistically significant differences (t-test), **P < 0.01. Representative images of lung morphology and lung metastatic nodules formed by MYLK4-knockdown 143B cells and control cells were shown in the left panel. Corresponding HE staining was shown in the middle panel. Scale bars = 100 μm.
speculated that if MYLK4 could directly phosphorylate EGFR. Thus, we constructed a truncate of EGFR which owned the intracellular tyrosine kinase domain (aa 668–1210). Then, His-tag pull-down assay was carried out to determine whether there is a direct interaction between MYLK4 and EGFR (668–1210) in vitro. MYLK4 and EGFR (668–1210) were bacterially expressed and purified as GST and His-tag fusion proteins, respectively. As shown in Supplementary Fig. 4B, GST-MYLK4, but not GST, bound to His-tagged EGFR, indicating direct binding between these proteins in vitro. Then, we further test whether MYLK4 can phosphorylate EGFR through kinase assay in vitro. As shown in Supplementary Fig. 4C, EGFR was phosphorylated by MYLK4. Collectively, these findings suggest that MYLK4 is associated with p-EGFR (Y1068).

We then tested whether MYLK4-mediated OS migration and invasion was depend on EGFR signaling pathway. Our results showed that EGFR overexpression could partially reverse the inhibition of OS cell
migration and invasion caused by MYLK4 knockdown (Supplementary Fig. 5A, C and D). We also found the EGFR inhibitor gefitinib partially reversed the promotion of cell migration and invasion caused by overexpression of MYLK4 (Supplementary Fig. 5B, E and F). Therefore, our results indicated that MYLK4 promoted OS progression through the activation of the EGFR signaling pathway.

MYLK4 inhibitor ML-7 and EGFR inhibitor gefitinib synergize in suppressing the growth and metastasis of OS in vitro and in vivo

Since MYLK4 promotes the OS progress via the EGFR signal pathway, we attempt to combine the MYLK4 inhibitor with the EGFR inhibitor in order to see whether this combination synergistically inhibits the growth and metastasis of osteosarcoma in vitro and in vivo. First, we observed that the OS cell line 143B and HOS displayed time-dependent and concentration-dependent cell viability suppression with ML-7 or gefitinib treatment (Supplementary Fig. 6A-D). The IC50 values in 143B and HOS cells at 48 h were 50.66 and 51.4 μM for ML-7 and 36.2 and 40 μM for gefitinib, respectively. Combined treatment obviously restrained cell viability compared with that observed with monotherapy of either gefitinib or ML-7 (Fig. 6a and b). We also observed synergy at different combination concentrations, especially at lower concentrations (Fig. 6a and b).
Fig. 5 (See legend on next page.)
Furthermore, the combination of gefitinib and ML-7 exhibited a synergistic repressive effect on cell proliferation, metastasis, and invasion compared with that observed with monotreatment (Fig. 6c-e). Then, we further confirmed this result using orthotopic xenograft models, which were divided into four groups: control group, gefitinib and ML-7 single drug treated group and gefitinib plus ML-7 treated group. HE staining showed fewer pulmonary metastatic nodules in the group treated with Gefitinib plus ML-7 compared with those observed in the monotherapy and control groups (Fig. 6f). As shown in Fig. 6g, the combination treatment contributed to a more obvious anti-tumor effect compared with that in the monotherapy groups, as determined by tumor weight. Western blotting showed that the combination treatment had an increased inhibiting effect on the EGFR signal pathway and the downstream MAPK and AKT signal pathways in vitro and in vivo compared with that observed for monotreatment with either gefitinib or ML-7 (Fig. 6h and i). Therefore, these results demonstrated that the combination therapy of MYLK4 and EGFR inhibitors suppressed growth and metastasis to a greater extent than monotherapy.

**Discussion**

In our study, we first comprehensively analyzed the role of MYLK4 in the regulation of growth and metastasis of OS. We discovered that MYLK4 expression was not only higher in OS tissues (compared with normal human osteoblasts) but also showed higher expression in patients with OS and metastases (compared with the non-metastasis group). Furthermore, MYLK4 overexpression promoted the proliferation and metastasis of OS cells. On the contrary, MYLK4 knockdown inhibited their proliferation and metastasis. Moreover, MYLK4 interacted with the EGFR and promoted growth and metastasis through the EGFR signaling pathway. Furthermore, the MYLK4 inhibitor ML-7 and the EGFR inhibitor gefitinib synergize in suppressing OS growth and metastasis in vitro and in vivo.

MYLK, as one member of MYLK family, is important to cell adhesion, which is a process central to metastasis and migration [24]. In hepatocellular carcinoma, Lin et al. showed MYLK had higher expression in human HCC than adjacent liver specimens [25]. Consistent with this notion, we detected the expression of all four members of the MYLK family in the TARGET database and found MYLK4 had high expression in metastatic OS tissues. Furthermore, an independent GEO database, showed that MYLK4 had a higher expression in OS tissues than in normal human osteoblasts. Through the univariate Cox proportional regression analysis, MYLK4 was found to be related to the poor prognosis of patients with OS in the TARGET database.

Prior studies have shown that MYLK can phosphorylate MLC and that suppression of MLC phosphorylation causes failure of cytokinesis and results in multipolarity in cancer cells [26]. MLC is a critical step in facilitating the association between myosin and F-actin, which may generate a contractile force [27]. Recent studies found that cytoskeleton rearrangement had a strong relationship with EMT [28], which has vital roles in the invasion and metastasis of mesenchymal-derived tumors such as OS [29]. Consistently, we found that overexpression of MYLK4 increased the expression of N-cadherin, Twist and Snail and decreased the expression of E-cadherin; this reaction promoted EMT progress, which resulted in increased metastasis of OS cells. Moreover, MYLK4 knockdown decreased the expression of N-cadherin, Twist and Snail and increased the expression of E-cadherin; this restrained the EMT progress, which resulted in decreased metastasis of OS cells. To further demonstrate the role of MYLK4 in OS metastasis, we constructed MYLK4-knockdown orthotopic OS-implanted mice and found knockdown of MYLK4 restrained lung metastasis of OS more than that in the control group. Transforming growth factor-β (TGF-β) signaling is one of the most vital EMT inducers, which is an important process in tumor development, resulting in cancer cell migration and invasion [30]. Consistently, in our study, expression of MYLK4 was up regulated after TGF-β stimulation; however, MYLK4 knockdown retarded EMT progress induced by TGF-β. Targeting myosin light chain kinase with kinase inhibitors might be an effective strategy to inhibit tumor metastasis. Cui et al. showed that ML-7, a kinase inhibitor of myosin light chain kinase, restrained the development of breast cancer cells via the p38 pathway [31]. Moreover, also in breast cancer cells, Zhou et al. found ML-7 restrained proliferation and migration of breast cancer through ERK1/2 signaling pathway [32]. These results were in keeping with our research as we found ML-7 could suppress the proliferation and migration of OS cells in vitro and vivo. Collectively,
Fig. 6 (See legend on next page.)
our results suggest that MYLK4 influences the development of OS.

Cancer cell migration is a complex process wherein multiple signaling molecules participate. Signaling cascades initiated by adhesion molecules or growth factor receptors (such as the EGFR control cell migration [33]. EGFR is a member of the ErbB family and has important roles in essential cellular functions including proliferation and invasion [15]. Previous studies have shown that the EGFR signal pathway has a vital role in OS progression. Lin et al. demonstrated that physakengose G induced apoptosis of OS cells through EGFR/mTOR signaling [34]. Yuan et al. found that MAT2B promotes proliferation of OS cells by targeting the EGFR signaling [35]. Consistent with this notion, through mass spectrometry analysis, we found EGFR was a new binding protein of MYLK4. Overexpression of MYLK4 promoted EGFR and the downstream signaling pathway. However, MYLK4 knockdown suppressed EGFR and the downstream signaling pathway. Moreover, in OS tissue microarray analysis, the expression of MYLK4 showed a positive correlation with p-EGFR. Furthermore, our results demonstrated that EGFR overexpression could partially reverse the inhibition of OS cell migration and invasion caused by MYLK4 knockdown. Conversely, the EGFR inhibitor gefitinib could partially reverse the promotion of cell migration and invasion by MYLK4 overexpression. Epidermal growth factor (EGF) is the main ligand that specifically binds to the EGFR. Excitation of the EGF/EGFR signaling pathway promotes the proliferation and invasion of cancer cells [36]. In the present study, EGF activated the EGFR signaling pathway in OS and knockdown of MYLK4 could restrain the EGFR signaling pathway induced by EGF. Son et al. showed that enhanced EGFR signaling via upregulated TGF-β signaling promoted cell migration and invasion in human oral squamous cell carcinoma [37]. In diabetic nephropathy, Chen et al. showed that EGFR transactivation was crucial for TGFβ/Smad3 activation and renal fibrosis [38].

In lung adenocarcinoma, Du et al. found that TGF-β-induced factor homeobox 2 mediated the EGRF-RAS-ERK signaling pathway to enhance the stemness of cancer cells [39]. In live cancer, TGF-β could upregulate the expression of EGFR ligands, which transactivated the EGFR pathway, counteracting its pro-apoptotic response [40]. Therefore, TGF-β signaling and EGFR signaling have a cross talk. Therefore, we conclude that MYLK4's influence on OS progression is dependent on the EGFR signaling pathway.

One of the hallmarks of tumors is the proliferative signaling that is continuously activated. Based on this, the FDA has approved numerous small-molecule kinase inhibitors in clinical practice for the treatment of cancer patients [41]; tyrosine kinase inhibitors were deemed a valid therapeutic means for many cancer types [42]. In recent studies, Maloney et al. showed that gefitinib could inhibit the metastasis of OS through macrophage receptor interacting protein kinase 2 (RIPK2) [43]. Sakurai et al. proved that gefitinib inhibits the growth of prostate cancer and OS through inhibition of cyclin G-associated kinase (GAK) [44]. Consistently, we also found gefitinib could inhibit the growth and metastasis of OS in vitro and vivo. However, a number of studies showed that OS cells had resistance to EGFR inhibitors and the resistance could be overcome by combination with other treatment. Ji et al. demonstrated that combined EGFR/STAT3 inhibition could overcome resistance of EGFR inhibition [45]. In another study, Gvozdenovic et al. found that co-targeting of IGF-IR and EGFR signaling was a useful therapeutic strategy to overcome resistance EGFR inhibitors in OS [46]. Consistently, we found that combined MYLK4 inhibitor ML-7 and EGFR inhibitor gefitinib had a synergistic effect in restraining the proliferation and metastasis of OS cells in vivo and in vitro. Therefore, a combination therapy of MYLK4 and EGFR inhibitors could be a novel treatment strategy for OS. The detailed molecular mechanism deserves further investigation.
Conclusions
In conclusion, our findings demonstrate that the function of growth and metastasis in OS cells could be regulated by MYLK4 via the EGFR signaling pathway. This is the first study to show that the combination therapy of MYLK4 and EGFR inhibitors may act as a potential therapeutic approach for OS. These data indicated that MYLK4 can be a potential diagnostic and therapeutic target in patients with OS.

Abbreviations
OS: Osteosarcoma; MYLK4: Myosin Light Chain Kinase Family Member 4; EGFR: Epidermal growth factor receptor; IP: immunoprecipitation; EGF: Epidermal growth factor; IHC: Immunohistochemistry; TARG: EGFR: Epidermal growth factor receptor; IP: immunoprecipitation; OS: Osteosarcoma; MYLK4: Myosin Light Chain Kinase Family Member 4; Abbreviations

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13046-021-01965-z.

Additional file 1: Figure S1. Expression of Myosin Light Chain Kinase family members in database and OS cell lines. Expression of MYLK A), MYLK2 B), and MYLK3 C) between non-metastasis and metastasis osteosarcoma samples in TARGET database. Expression of MYLK D), MYLK2 E), MYLK3 F) and MYLK4 G) between normal human osteoblasts and OS tumor samples in GSE12865. H) Expressions of MYLK4 in OS cell lines which were detected by western blotting. Statistically significant differences (t-test), NS, nonsignificant, *P < 0.05.

Additional file 2: Figure S2. Induced EMT in OS can be suppressed by knockdown of MYLK4. A) The expression of MYLK4 was detected by western blotting in the induction by TGF-β (10 ng/ml). B) The expression of EMT markers was detected by western blotting in MYLK4-down knockdown cells and the control cells induced by TGF-β (10 ng/ml).

Additional file 3: Figure S3. Knockdown of MYLK4 expression alters cytoskeleton organization. Knockdown of MYLK4 leads a decrease of F-actin stress fibers and disorganization of F-actin architectures.

Additional file 4: Figure S4. MYLK4 interacts with EGFR and phosphorylates EGFR. A) Pan-Tyr of MYLK4 was detected with or without Gefitinib in Flag-MYLK4 143B cells. B) His-tag pull-down assay was performed to investigate the direct interaction between MYLK4 and EGFR. C) An in vitro kinase assay for the detection of EGFR phosphorylation.

Additional file 5: Figure S5. The function of MYLK4 is dependent on EGFR signaling. A) The expression of p-EGFR, p-AKT and p-ERK were detected by western blotting in MYLK4 knockdown cell and the control cell after co-transfecting with indicated plasmids for 48 h. B) The expression of p-EGFR, p-AKT and p-ERK were detected by western blotting in MYLK4 overexpression cell treated by indicated gefitinib (25 μM) or dmsos for 48 h. C) Wound healing assay was carried out in MYLK4 knockdown cell after co-transfecting with indicated plasmids for 48 h. Representative images of migration were shown in the upper panel. The proportions of invading cells were shown in the histogram. The bars indicate the mean ± s.d. Statistically significant differences (t-test, **P < 0.01, Scale bars = 250 μm). D) Transwell assay was carried out in MYLK4 knockdown cell and the control cell after co-transfecting with indicated plasmids for 48 h. Representative images of invasion were shown in the upper panel. The proportions of invading cells were shown in the histogram. The bars indicate the mean ± s.d. Statistically significant differences (t-test), **P < 0.01, Scale bars = 200 μm. E) Wound healing assay was carried out in MYLK4 overexpression cells treated by indicated gefitinib (25 μM) or dmsos. Representative images of migration were shown in the upper panel. The proportions of invading cells were shown in the histogram. The bars indicate the mean ± s.d. Statistically significant differences (t-test, **P < 0.01, Scale bars = 200 μm). F) Transwell assay was carried out in MYLK4 overexpression cells treated by indicated gefitinib (25 μM) or dmsos. Representative images of invasion were shown in the upper panel. The proportions of invading cells were shown in the histogram. The bars indicate the mean ± s.d. Statistically significant differences (t-test, **P < 0.01, Scale bars = 200 μm).

Acknowledgements
We thank all members of Shanghai Bone Tumor Institute for their assistance.

Authors’ contributions
ZDC, TZ, WS, YQH conceived and designed the study; MKY, YFZ, XJM collected subjects and clinical data; HJ, KZ, YFJ analyzed the data; ZYW, JX revised the manuscript; MKY, TZ wrote the manuscript; All authors reviewed and approved the final manuscript.

Funding
This work was supported by NSFC (81874124, 81772859, 81872177); Shanghai Science and Technology Committee Rising-Star Program (19QA1407200); Shanghai Municipal Health Commission (2018YQ18).

Availability of data and materials
The datasets analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The animal experiments were approved by the Animal Research Committee of the Shanghai General Hospital (Ethical code: 2019A0004) and were performed in accordance with established guidelines.

Consent for publication
Consent for publication was obtained from the participants.

Competing interests
The authors declare no conflict of interest.

Received: 17 November 2020 Accepted: 26 April 2021 Published online: 12 May 2021

References
1. Rosenberg AE. WHO classification of soft tissue and bone, fourth edition: summary and commentary. Curr Opin Oncol. 2013;25:571–3.
2. Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res. 2008;466:1114–30.
3. Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res. 2010;5:78.
4. Pires E, Perry SV, Thomas MA. Myosin light-chain kinase, a new enzyme phosphorylates EGFR. PLoS One. 2007;2(9):e866.
5. Kamm KE, Stull JT. Signaling to myosin regulatory light chain in sarcomeres. Biomed Pharmacother. 2017;92:810–8.
6. Li HS, Lin Q, Wu J, Jiang ZH, Zhao JB, Pan J, et al. Myosin light-chain kinase, a new enzyme phosphorylates EGFR. FEBS Lett. 1994;352:292–6.
7. Kamm KE, Stull JT. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res. 2010;5:78.
8. Li HS, Lin Q, Wu J, Jiang ZH, Zhao JB, Pan J, et al. Myosin light-chain kinase, a new enzyme phosphorylates EGFR. FEBS Lett. 1994;352:292–6.
9. Kamm KE, Stull JT. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res. 2010;5:78.
10. Li HS, Lin Q, Wu J, Jiang ZH, Zhao JB, Pan J, et al. Myosin light-chain kinase, a new enzyme phosphorylates EGFR. FEBS Lett. 1994;352:292–6.
11. Kamm KE, Stull JT. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res. 2010;5:78.
12. Li HS, Lin Q, Wu J, Jiang ZH, Zhao JB, Pan J, et al. Myosin light-chain kinase, a new enzyme phosphorylates EGFR. FEBS Lett. 1994;352:292–6.
9. Kong FE, Tang YQ, Gong YF, Mo QJ, Zhao Y, Li MM, et al. Identification of prognostic claudins signature in hepatocellular carcinoma from a hepatocyte differentiation model. Hepatol Int. 2020;14:521–33.

10. Islam YF, Joseph R, Chowdhury RR, Anderson RH, Kasahara H. Heart failure induced by perinatal ablation of cardiac myosin light chain kinase. Front Physiol. 2016;7:480.

11. Herer J, Roselló-Ulier E, Rivera M, Molina-Navarro MM, Tarazon E, Ortega A, et al. RNA-sequencing analysis reveals new alterations in cardiomyocyte cytoskeletal genes in patients with heart failure. Lab Invest. 2014;94:645–53.

12. Lee RD, Song MY, Lee JK. Large-scale profiling and identification of potential regulatory mechanisms for allelic gene expression in colorectal cancer cells. Gene. 2013;512:216–22.

13. Schlessinger J. Receptor tyrosine kinases: legacy of the first two decades. Cold Spring Harb Perspect Biol. 2014;6a00912.

14. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012;12:553–63.

15. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25:282–303.

16. Linder M, Giltzner E, Srivatsa S, Bakiri L, Matsuoka K, Shahrouzi P, et al. EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling. EMBO Mol Med. 2018;10:e9408.

17. Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19:1389–400.

18. Perry JA, Kiezun A, Toniz P, Van Allen EM, Carter SL, Baca SC, et al. Complementary genomic approaches highlight the P38Km/MTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014;111:E564–73.

19. Martellini E, De Palma R, Ordutra M, De Vita F, Cardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol. 2009;158:1–9.

20. Brennan RC, Furman W, Mao S, Wu J, Turner DC, Stewart CF, et al. Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol. 2014;74:1191–8.

21. Su Y, Luo X, He BC, Wang Y, Chen L, Zuo GW, et al. Establishment and characterization of a newly metastatic human osteosarcoma cell line. Clin Exp Metastasis. 2009;26:599–610.

22. Zhang T, Li J, Yin F, Lin B, Wang Z, Xu J, et al. Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3. Proc Natl Acad Sci U S A. 2014;111:E5564–73.

23. Feigin ME, Muthuswamy SK. ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion. Exp Cell Res. 2009;315:707–16.

24. Lin H, Zhang C, Zhang H, Xia YZ, Zhang CY, Luo J, et al. Physakengose G induces apoptosis via EGFR/mTOR signaling and inhibits autophagic flux in human osteosarcoma cells. Phytomedicine. 2018;42:190–8.

25. Yuan Y, Wang Y, Liu Z, Sun Y, Yao Y, Wu W, et al. MAT2B promotes proliferation and inhibits apoptosis in osteosarcoma by targeting epidermal growth factor receptor and proliferating cell nuclear antigen. Int J Oncol. 2019;54:2019–29.

26. Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12:23–20.

27. Son HK, Kim D, Lim Y, Kim J, Park I. A novel TGF-β receptor II mutation (I227T/N236D) promotes aggressive phenotype of oral squamous cell carcinoma via enhanced TGF-β signaling. BMC Cancer. 2020;20:1163.

28. Chen J, Chen JK, Nagai K, Pileth D, Tan M, Lee TC, et al. EGFR signalling promotes TGFβ-dependent renal fibrosis. J Am Soc Nephrol. 2012;23:215–24.

29. Dr R, Shen W, Liu Y, Gao W, Zhou W, Li J, et al. TGF2 promotes the progression of lung adenocarcinoma by bridging EGFR/ERK/ERK signaling to cancer stemness. Signal Transduct Targeted Ther. 2019;4:60.

30. Caja L, Sancho P, Bertran F, Fabregat I. Dissecting the effect of targeting the epidermal growth factor receptor on TGF-β-induced-apoptosis in human hepatocellular carcinoma cells. J Hepatol. 2011;55:351–8.

31. Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharm Res. 2020;2020;152:104609.

32. Serrano C, Leal A, Koyan G, Morgan JA, Bavyanskas CM, Phallen J, et al. Phase I study of rapid alternation of Sunitinib and Regorafenib for the treatment of tyrosine kinase inhibitor refractory gastrointestinal stromal tumors. Clin Cancer Res. 2019;25:7287–93.

33. Maloney C, Kallis MP, Edelman M, Tzanavaris C, Lesser M, Soffer SZ, et al. Gefitinib inhibits invasion and metastasis of osteosarcoma via inhibition of macrophage receptor interacting serine-threonine kinase 2. Mol Cancer Ther. 2020;19:1340–50.

34. Sakurai MA, Ozaki Y, Okuzaki D, Naito Y, Sasakura T, Okamoto A, et al. Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630. PLoS One. 2014;9:e100124.

35. Ji XL, He M. Sodium cantharidate targets STAT3 and abrogates EGFR receptor inhibition in osteosarcoma. Aging. 2019;11:5848–63.

36. Gvozdevnic A, Boro A, Born W, Muff R, Fuchs B. A bispecific antibody targeting IGF-IR and EGFR has tumor and metastasis suppressive activity in an orthotopic xenograft osteosarcoma mouse model. Am J Cancer Res. 2017;7:1435–49.